vs

Side-by-side financial comparison of Marvell Technology, Inc. (MRVL) and ResMed (RMD). Click either name above to swap in a different company.

Marvell Technology, Inc. is the larger business by last-quarter revenue ($2.1B vs $1.4B, roughly 1.5× ResMed). Marvell Technology, Inc. runs the higher net margin — 91.7% vs 27.6%, a 64.1% gap on every dollar of revenue. On growth, Marvell Technology, Inc. posted the faster year-over-year revenue change (36.8% vs 11.0%). Over the past eight quarters, Marvell Technology, Inc.'s revenue compounded faster (20.6% CAGR vs 7.9%).

Marvell Technology, Inc. is an American company, headquartered in Santa Clara, California, which develops and produces semiconductors and related technology. Founded in 1995, the company had more than 6,500 employees as of 2024, with over 10,000 patents worldwide, and an annual revenue of $5.5 billion for fiscal 2024.

ResMed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19.

MRVL vs RMD — Head-to-Head

Bigger by revenue
MRVL
MRVL
1.5× larger
MRVL
$2.1B
$1.4B
RMD
Growing faster (revenue YoY)
MRVL
MRVL
+25.9% gap
MRVL
36.8%
11.0%
RMD
Higher net margin
MRVL
MRVL
64.1% more per $
MRVL
91.7%
27.6%
RMD
Faster 2-yr revenue CAGR
MRVL
MRVL
Annualised
MRVL
20.6%
7.9%
RMD

Income Statement — Q3 FY2026 vs Q4 FY2026

Metric
MRVL
MRVL
RMD
RMD
Revenue
$2.1B
$1.4B
Net Profit
$1.9B
$392.6M
Gross Margin
51.6%
61.8%
Operating Margin
17.2%
34.6%
Net Margin
91.7%
27.6%
Revenue YoY
36.8%
11.0%
Net Profit YoY
381.1%
13.9%
EPS (diluted)
$2.20
$2.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MRVL
MRVL
RMD
RMD
Q2 26
$1.4B
Q4 25
$2.1B
$1.4B
Q3 25
$2.0B
$1.3B
Q2 25
$1.9B
$1.3B
Q1 25
$1.8B
$1.3B
Q4 24
$1.5B
$1.3B
Q3 24
$1.3B
$1.2B
Q2 24
$1.2B
$1.2B
Net Profit
MRVL
MRVL
RMD
RMD
Q2 26
$392.6M
Q4 25
$1.9B
$392.6M
Q3 25
$194.8M
$348.5M
Q2 25
$177.9M
$379.7M
Q1 25
$200.2M
$365.0M
Q4 24
$-676.3M
$344.6M
Q3 24
$-193.3M
$311.4M
Q2 24
$-215.6M
$292.2M
Gross Margin
MRVL
MRVL
RMD
RMD
Q2 26
61.8%
Q4 25
51.6%
61.8%
Q3 25
50.4%
61.5%
Q2 25
50.3%
60.8%
Q1 25
50.5%
59.3%
Q4 24
23.0%
58.6%
Q3 24
46.2%
58.6%
Q2 24
45.5%
58.5%
Operating Margin
MRVL
MRVL
RMD
RMD
Q2 26
34.6%
Q4 25
17.2%
34.6%
Q3 25
14.5%
33.4%
Q2 25
14.3%
33.7%
Q1 25
12.9%
33.0%
Q4 24
-46.4%
32.5%
Q3 24
-7.9%
31.6%
Q2 24
-13.1%
31.2%
Net Margin
MRVL
MRVL
RMD
RMD
Q2 26
27.6%
Q4 25
91.7%
27.6%
Q3 25
9.7%
26.1%
Q2 25
9.4%
28.2%
Q1 25
11.0%
28.3%
Q4 24
-44.6%
26.9%
Q3 24
-15.2%
25.4%
Q2 24
-18.6%
23.9%
EPS (diluted)
MRVL
MRVL
RMD
RMD
Q2 26
$2.68
Q4 25
$2.20
$2.68
Q3 25
$0.22
$2.37
Q2 25
$0.20
$2.58
Q1 25
$0.23
$2.48
Q4 24
$-0.78
$2.34
Q3 24
$-0.22
$2.11
Q2 24
$-0.25
$1.97

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MRVL
MRVL
RMD
RMD
Cash + ST InvestmentsLiquidity on hand
$2.7B
$1.4B
Total DebtLower is stronger
$4.5B
$663.8M
Stockholders' EquityBook value
$14.1B
$6.3B
Total Assets
$21.6B
$8.5B
Debt / EquityLower = less leverage
0.32×
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MRVL
MRVL
RMD
RMD
Q2 26
$1.4B
Q4 25
$2.7B
$1.4B
Q3 25
$1.2B
$1.4B
Q2 25
$885.9M
$1.2B
Q1 25
$948.3M
$932.7M
Q4 24
$868.1M
$521.9M
Q3 24
$808.7M
$426.4M
Q2 24
$847.7M
$238.4M
Total Debt
MRVL
MRVL
RMD
RMD
Q2 26
$663.8M
Q4 25
$4.5B
$403.9M
Q3 25
$4.5B
$408.7M
Q2 25
$4.2B
$658.4M
Q1 25
$4.1B
$663.1M
Q4 24
$4.1B
$662.9M
Q3 24
$4.1B
$667.6M
Q2 24
$4.1B
$697.3M
Stockholders' Equity
MRVL
MRVL
RMD
RMD
Q2 26
$6.3B
Q4 25
$14.1B
$6.3B
Q3 25
$13.4B
$6.1B
Q2 25
$13.3B
$6.0B
Q1 25
$13.4B
$5.5B
Q4 24
$13.4B
$5.3B
Q3 24
$14.2B
$5.2B
Q2 24
$14.5B
$4.9B
Total Assets
MRVL
MRVL
RMD
RMD
Q2 26
$8.5B
Q4 25
$21.6B
$8.5B
Q3 25
$20.6B
$8.3B
Q2 25
$20.0B
$8.2B
Q1 25
$20.2B
$7.6B
Q4 24
$19.7B
$7.1B
Q3 24
$20.3B
$7.2B
Q2 24
$20.5B
$6.9B
Debt / Equity
MRVL
MRVL
RMD
RMD
Q2 26
0.11×
Q4 25
0.32×
0.06×
Q3 25
0.33×
0.07×
Q2 25
0.32×
0.11×
Q1 25
0.30×
0.12×
Q4 24
0.31×
0.13×
Q3 24
0.29×
0.13×
Q2 24
0.29×
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MRVL
MRVL
RMD
RMD
Operating Cash FlowLast quarter
$582.3M
Free Cash FlowOCF − Capex
$508.8M
FCF MarginFCF / Revenue
24.5%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
0.31×
TTM Free Cash FlowTrailing 4 quarters
$1.6B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MRVL
MRVL
RMD
RMD
Q2 26
Q4 25
$582.3M
$339.7M
Q3 25
$461.6M
$457.3M
Q2 25
$332.9M
$538.8M
Q1 25
$514.0M
$578.7M
Q4 24
$536.3M
$308.6M
Q3 24
$306.4M
$325.5M
Q2 24
$324.5M
$440.1M
Free Cash Flow
MRVL
MRVL
RMD
RMD
Q2 26
Q4 25
$508.8M
$311.2M
Q3 25
$414.1M
$414.4M
Q2 25
$214.1M
$508.2M
Q1 25
$444.1M
$557.9M
Q4 24
$461.3M
$288.0M
Q3 24
$258.2M
$307.7M
Q2 24
$233.0M
$415.2M
FCF Margin
MRVL
MRVL
RMD
RMD
Q2 26
Q4 25
24.5%
21.9%
Q3 25
20.6%
31.0%
Q2 25
11.3%
37.7%
Q1 25
24.4%
43.2%
Q4 24
30.4%
22.5%
Q3 24
20.3%
25.1%
Q2 24
20.1%
33.9%
Capex Intensity
MRVL
MRVL
RMD
RMD
Q2 26
Q4 25
3.5%
2.0%
Q3 25
2.4%
3.2%
Q2 25
6.3%
2.3%
Q1 25
3.8%
1.6%
Q4 24
4.9%
1.6%
Q3 24
3.8%
1.5%
Q2 24
7.9%
2.0%
Cash Conversion
MRVL
MRVL
RMD
RMD
Q2 26
Q4 25
0.31×
0.87×
Q3 25
2.37×
1.31×
Q2 25
1.87×
1.42×
Q1 25
2.57×
1.59×
Q4 24
0.90×
Q3 24
1.05×
Q2 24
1.51×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons